Answers are grounded in this paper and cite their sources.
Objective: To analyze the metabolic evolution in patients with previous poor control after starting treatment with canagliflozin.Methodology: A retrospective observational study in patients with poor glycemic control assigned to several health centers of Albacete and Cuenca provinces in which treatment with canagliflozin has been started after 6 months. Variables are analyzed: age, sex, weight, height, BMI. Analytical variables: glycemia, glycated hemoglobin, total cholesterol, HDL, LDL, triglycerides, uric acid, C-reactive protein, urea, creatinine proteinuriaResults: 107 diabetic patients participated, 45.5% men, Average age 61, 16-23 years. Basal variable 6 months level signify Glucemia fasting 157.41-126.89, p>0.002 Hemoglobin glycated 8.55-6.91, p>0.003, Weight 84.31-80.21, p>0.002, BMI 31.66-30.04, p>0.04, Cholesterol T 199.05-188.61, p>0.03, LDL 113.36-97.102, p>0.05, TG 195.18-176.80, p>0.05.Conclusion: The treatment with Canaglifozin 100 has been effective for the metabolic control of patients previously poorly controlled.
No takes yet. Share an insight, caveat, or question.
López et al. (2018) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: